← Grifols SA (GRFS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Grifols SA (GRFS)
Pharmaceutical Preparations · market cap $5.0B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-05 (est.)
Earnings
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Grifols S.A. (GRFS) is a Barcelona-founded, 117-year-old global plasma-derived medicines company with ~23,800 employees serving 110+ countries, currently trading at ~$7.27 with a market cap of ~$4.96B. The company operates a deep, plasma-centric pipeline spanning hemostasis, immunology, alpha-1 antitrypsin deficiency (AATD), and rare disease, with multiple Phase 3 programs. The most near-term high-impact catalyst is an estimated August 2026 Phase 3 data readout for Alpha-1 MP in Alpha-1 Antitrypsin Deficiency, rated 9/10 importance.
The catalyst path
- 2026-10-05 (est.)Earningsimp 5/10
- 2027-09-30 (est.)Phase 3 · Alpha-1 15%imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| FS Grifols | Phase 3 | Target Bleeding Site During Peripheral Vascular Surgery |
| Liquid Alpha₁-PI | Phase 3 | Alpha₁-Antitrypsin Deficiency |
| Immune Globulin Intravenous (Human) | Phase 2 | Immunologic Deficiency Syndrome |
| Convalescent anti-SARS-CoV-2 MBT Plasma | Phase 2 | COVID-19 |
| Prolastin-C, 60 mg/kg | Phase 2 | Emphysema |
| GRF312 5% | Phase 2 | Dry Eye Disease |
| Prolastin | Phase 2 | COVID-19 |
| Human thrombin | Phase 2 | Hemostasis |
| Alpha-1 MP | Phase 3 | Alpha 1-Antitrypsin Deficiency |
| Albutein 20% | Phase 3 | Decompensated Cirrhosis and Ascites |
| BeneFIX | Phase 2 | Hemophilia B |
| Albumin (Human) 20%, United States Pharmacopeia (USP) | Phase 2 | Alpha 1-Antitrypsin Deficiency |
| alpha-1 proteinase inhibitor (human) | Phase 3 | Alpha 1-Antitrypsin Deficiency |
| Fibrin Sealant (FS) Grifols | Phase 3 | Soft Tissue Surgical Bleeding |
| IVIG-PEG | Phase 3 | Primary Immunodeficiency |
| Intravenous Immune Globulin | Phase 2 | COVID-19 |
| Albumin | Phase 2 | Amyotrophic Lateral Sclerosis |
| Fibrin Sealant Grifols | Phase 3 | Excessive Bleeding During Surgery |
| Specific intravenous anti-hepatitis B immunoglobulin | Phase 3 | Hepatitis B, Chronic |
| IGIV3I Grifols | Phase 3 | Immune (Idiopathic) Thrombocytopenic Purpura |
Price & technical context
3-month
+2.0%
6-month
-11.5%
12-month
-26.7%
52-wk range
$7.02–$10.02
vs 50-day MA
-5.5%
vs 200-day MA
-10.6%
Realized vol
31.8%
Max drawdown
-35.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GRFS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.